Snowie is Back!
Followers | 126 |
Posts | 15,568 |
Boards Moderated | 1 |
Alias Born | 03/19/2010 |
Twitter Profile: | Temporarily Unavailable |
Follow on Twitter: | Follow @ Temporarily Unavailable |
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Look at the Bid and Ask Spread
Lots of confidence on the part of ENTB stockholders, it looks like to me. Bidders are trying to get in on the new ground floor (2.00), which is a .10 improvement on the opening, too. Nice, strong stock this week, is my guess. I think it stays above that new ground floor even on end-of-day profit taking activities.
Looks like the price was just bid up, almost back to its high today. That's nice, considering it's only 1:00PM on the East Coast.
Bronchitis? ENTB Can Help With That
The great thing about this company-outside of the stock performance (and it's been exceptional today, generally speaking) itself-is that the work it's doing may eventually lead to therapies that could address issues like bronchial inflammation and similar illnesses.
I suspect that much, if not all, of the conditions that afflict us have at their base a genetic component, either wholly or in part. If you can unlock that key and make use of certain stem cell modalities to treat them, then the sky's literally the limit!
The price fell back just a smidgen on sell-offs and profit taking. I'd watch the next few hours to see if pressure builds up again before a final PM sell-off and profit taking occurs.
ENTB Up Nearly 11% Today
Strong volume and end-of-day sell-offs yesterday didn't depress the price all that much. It opened strong and it's been hold steady at 2.10 for the last half-hour or so. I'd say that it might be something to profit from at the end of the day today, or get into it in the morning tomorrow and then ride it for a while before cutting it loose. It looks like a likely winner, to me.
The company's got a lot going for it in the biotech sector because it has a lock on certain biomedical information applications that the government's bound to start awarding research funding to, now that health care reform's been signed into law (and with the prospect that NIH will be getting a chunk of $$ from the government to push certain stem cell and other research items that ENTB's big in).
Keep an Eye on ENTB (up nearly 11%)
It's up nearly 11% since the open this morning and it looks to be a strong performer. Trading volume's high, so I'm going to watch for sell-off and profit taking at the end of the day but it's been a good bet for much of last week, and sell-offs yesterday look to have established a new floor below which I don't think it's going fall. ENTB's a strong biotech firm with a kind of lock on certain bioinformatics suites.
The CEO's got a good executive suite in place now, as well, and it's made two outstanding additions to the clinical and research side of the house. With HCR signed into law, I see more research funding flowing into the company's coffers, too. I think, given a bit of time, it can regain it's mid-6 52-week high.
Everybody's Impressed with ENTB
I agree. The stock's not performing with what would normally be considered rational behavior, but with health care reform signed in, and the "good" parts of the bill delivering the possibility of increased government funding of medical research (NIH will be turning that tap wide open pretty soon, especially in areas that ENTB's strong in), ENTB looks well-positioned to capitalize on that.
Trading volume's fairly high right now, and I think there's a lot of people that rushed in after that minor sell-off yesterday lowered the end-of-day price (which may have become the absolute bottom, right now, if everything stays as it is in terms of the company's position) to where folks felt comfortable in looking for an in-and-out series of plays for the day.
I'm going to watch volume over the last 1/4 of the day and watch for big profit-taking, but I don't think the stock will sink to yesterday's closing price and, right now, it looks ready to establish a new, higher, closing price that's sure to put a smile on a lot of peoples faces
The Beast of the East
And the West, the North and the South, apparently. It's got legs and it looks strong. Lots of folks out there are looking at this company with fresh eyes, I'd say. And it has the market cornered on bioinformatics suites when it comes to the fight against several serious medical conditions and diseases.
As word gets around about that, I think you'll see more capital investment and more than a few investors looking for a quick score come in from the cold. Investors will be looking for a place to park some funds and make money in the long term while we'll see, at least for this week, more than a few looking to make a play based on this stock's strong performance from last week and carrying into this one, so far.
Those quick strike folks may play a little havoc on end-of-day activities (what's the trading volume like right now?), but I don't think the stock will be going anywhere on a big negative slide anytime soon.
Maybe Even a 1+!
Continued strong upward movement. Where's Dovegra? Maybe she's out buying up all those shares?
ENTB looks good for the day. I think it'll establish a new 'new bottom' which is actually going to be very impressive and will be the base for a strong remaining week, in the short term. This stock has legs right now. Quite impressive
Confidence Rating 1
Confidence rating of 1 is my way of explaining "confidence interval." Instead using a wonky term like that (it comes from inferential statistics), I just say "1," as in "It's Numbah One in my book, dahling"
I give ENTB an outstanding "get it while it's hot" confidence rating of 1, on a scale of 1 to 5 (with a 5, you might have better luck making money on a Powerball lottery ticket...LOL!)
As You Said: Excellent(8.4% Improvement)
Looks good, and the bid/ask prices are close. Looks like a very strong performer right now. As I said in the post previous to this one; looks like it can be strong all day and many will look at the opening price as the basis from which it won't go under, even in the face of any big sell-offs later in the day.
Let's see how much profit-taking goes on in the next round. That'll be a good clue as to its relative strength. I still give this stock a confidence rating of 1.
Now THAT's What I'm Talkin' About!
Nice upward move, and just as Dovegra and I finished talking about how the weaker-kneed among us had taken their profits yesterday and cleared out, opening the way for more than a few to get out at the 'new bottom.'
Let's hope it can sustain 2.04 and go even higher. It might fall back slight on end-of-day activities, but it looks strong right now and with a whole day of trading left to go!
Looks Like You're Right (ENTB Regained Value)
At least initially this morning, looks like the company's regained its value. Outside of watching the dips and then making a move on the margin on a quick strike in and out, I'm not usually a big fan of much more than a "buy and hold" strategy with predefined buy and sell points, but the OTCs and the like are certainly the place to dabble in in/out maneuvers. As long as you're not giving all the profit away in the form commissions, of course
At at any rate, I think ENTB's structure and what it does (biotech) makes it somewhat immune from broader fluctuations in the markets (of all types). True, a couple of pennies here can be significant, but I see a general upward progression in the near and long terms for ENTB. Let's see what the next hour brings.
Yes, a Few Cleared Out
It looks like a few late-afternoon sales dropped the price. I wonder what those who sold set for their asking price? It must've been low to drop the price per share to what it closed at.
Still, they look to have gotten in when it was probably at your famous 1.06/share and then made a sweet profit. It's also good (the final price per share) because it'll encourage a few folks to jump in tomorrow and, hopefully, we can expect to see another climb out.
Like you said; a nice ride while it lasted.
I Think They Made a Fool's Play
Too bad they got out too soon That last hour of activity looked like a fool's play to me. I'm no broker, and I wouldn't rate something a strong buy just on what I know about the ENTB's particulars right now, but I figure this stock as a good buy-and-hold candidate at least for this week.
Looks Like it's Certainly in Play Today
That last 2 hours of trading drove the price down. I wonder who was holding the stock and then dumped it? It can turn out to be a good thing, though, because it's got room for a regain and then a climb upwards now.
I still see the week ending on a high note. ENTB's just too strong and has too much going for it nowadays. I see a number of investors moving in to fill the void, if not today then tomorrow and for the rest of the week. I don't have a chart in front of me (I'm going to have to write myself a program to track this one, LOL!), but I can picture what's going to happen in the short term (long term prospects are still excellent, at minimum).
The last hour ought to be interesting when it comes to ENTB, for a fact.
Looks Like Somebody Became Afraid (or Greedy)
I noticed that movement over the last few trade executions. Looks like somebody (or a few somebodies) decided to consolidate his or her margin gains and then, like I say, "ran like they stole something."
Still 2 hours to go on ENTB. Let's see if there'll be a few that rush into the market now that it's supposedly rationalized its price to a point where they can get in, hold it at least a few days, and then get back out after it goes up even higher than its open this morning
Slow and Steady is the Way to Go
I agree. I'd rather see much less volatility when it comes to a stock, whether OTC or big boards. I like the way ENTB's been able to move, hold its value against trading and sell-off, and then move again.
Like I said; I was impressed by Friday's action because I was expecting an end-of-day downtick and ready to jump to secure a margin profit but apparently there's a LOT of investor confidence in ENTB (which I think is justified, no doubt).
As I also said earlier today: Confidence rating of 1 from me
ENTB Showing Strength Out of the Gate
Already at 2.02. Consensus rating of 1 to me Let's see what it can do throughout the day. Big spread between the bid and the ask and it seems to be getting the ask, which is a nice sign.
I think this stock has real staying power, which it's been gradually building over the last couple of weeks, especially.
I Agree Alj14; ENTB Looks Solid
The company definitely had a good week. It also looks like ENTB is making a concerted effort to focus attention on stem cell therapies in the treatment of a variety of illnesses, including cancer. This particular effort is a core competency of the company, and by pushing what Ewa Carrier had to say about progress in that arena, ENTB's showing it has what it takes to thrive.
As well; if it begins to look like ENTB has the upper hand in this part of the industry, I think investors will pump the stock nicely and more capital will move into this sector. And with ENTB ready to take advantage of this fact, the prospects for a nice move look better every day.
Okay, ENTB's Bid and Ask
.10 difference, when it closed on Friday, between the bid and the ask. That looked good. It held its own on end-of-day (and week) sell-offs last Friday and even gained .2 (that's even better).
I think, if things go right, it can keep a strong upward trend going and finish this week even better than it did last week. Here's to hoping the old 52-week high is squarely within this stock's sights. Certainly, I'm betting that it is.
Strong Close to a Good Week for ENTB
Yes, it did very well this week. It held its value even on end-of-day trading, when a lot of the weaker souls take their margin profits and run like they stole something
Friday, to me, was probably the best day of the week, for a number of reasons, including that it looked like it had bumped up on 1.98 and would drop a bit on sell-offs, but a mini-rally took place and it improved over the last hour, which was exceptional but which also shouldn't have been surprising, given what ENTB is bringing to the game.
I was also really impressed because the broader 'main' markets (NYSE etc.) took a bit of a hit on news of that South Korean Navy ship sinking (for a while, it looked like the North Koreans had torpedoed it) and lost some value throughout the day because of it.
This is another reason why I like the biotech sector, because it's a bit less-dependent on news like what went on in the Yellow Sea or even on issues like big oil refinery problems and the like. I think that over the long run, if one has more patience than just for the quick strike daily or intra-day moves, these kinds of stocks can deliver a real chance at significant upward moves.
Like I said; I can see ENTB regaining its old 52-week high in the mid-sixes and then moving up from there. They've made two outstanding acquisitions to their clinical executive staff (with Carrier the newest signing) and the executive suite looks to have a solid plan that's positioning the company for solid success in the near term and long term. For me, that gives it a solid rating. I'm excited for Monday the 29th to get here, already (LOL!).
C'mon Dover (ENTB)!
"C'mon Dover!" The famous words uttered by the Eliza Doolittle character played by the luminous Audrey Hepburn in the movie "My Fair Lady." 1.98 and a possibility that it could make 2.00? It could certainly happen, so my response is; "C'mon ENTB!"
Like I said; the company's very strong in biotech. It's got a great executive suite and a clinical trials director who's one of the best in the business. There's A LOT of room for a positive movement next week, for sure.
Shhh! ENTB's Our Secret
LOL! I think it's going to break out soon. I'm just hoping we can make out on it for awhile longer before we have to start sharing it with the plebeians who always come late to the game
At any rate, a rising tide does, after all, lift all boats. ENTB looks to be a strong rising tide that'll raise a great many boats in the near future!
I'm Liking What I'm Seeing from ENTB
Nice week and strong performance from this innovative biotech company. 3.00 definitely looks doable in the short term, especially if the company can stay focused on its R&D and its product services. It looks like ENTB's solid now in the peer review field as well.
The stock definitely looks like it could support concerted upward movement over the immediate future. In fact, 3.00 may be too conservative. I'm hoping to see its best 52-week high not too far down the road. Time to take a stronger position, I think. At minimum, I'm betting on a nice margin increase this week and next
I've been studying ENTB's revenue projections and cash flows (from the materials I could get online) and I think they've aligned their revenue projections with what they can reasonably expect over the next quarter or so. It definitely looks solid, which gives me the feeling that they're going to make a strong move upwards fairly soon. Certainly, given how they've performed this week (maintaining their increases against end-of-day activity), I think they're demonstrating real staying power nowadays.
Biotechs are always an area in which the particular biotech company has to do a great job of explaining – IN LAYMAN’S TERMS – just what their products are going to do and how successfully the company will perform in the markets. If they can do that, as ENTB is currently doing, they’ll THRIVE and not just survive. It’s good to see the company take an aggressive position in explaining what it’s doing, how it’s doing and how it’s going to go forward in the future. It helps convince investors that it’s got the juice, so to speak, and that’s a good thing!
Salutary Effects Help ENTB in Other Areas
I agree. When a biomed/tech company can demonstrate that it's able to apply a so-called "off-shelf" solution to other areas, a great deal of capital tends to migrate towards that company. There are good reasons for this is so, including the fact that very little in the way of resources will be needed for research and development.
When the R&D budget isn't impacted by the need to spend large amounts of money on developing secondary uses for a tech company's product it adds to the strength of the bottom line. More capital's available for other things, in other words. Like maybe a dividend, eventually (haha!).
But seriously, having a bottom line that'll be improved by a better cash position (cash that isn't going to improve or modify a product for other important uses) is sure to attract partners or increased amounts of capital investment. The ability to augment stem cell therapies is an exciting, untapped field of endeavor for many biomed companies. It's good to see that ENTB is being aggressive in promoting that aspect.
I also like that the company gained steadily again. That's a nice improvement from its close on the 22nd, to be honest. I figured maybe 1.83 but 1.85 was nice and a lot of money can be made on the margin if one's willing to time it properly. I'm more inclined, though, to ride it a bit longer. I actually think it can hit its 52-week high in the not-too-distant future if it can keep reporting these kinds of advances.
Nice End to a Good Day of Trading on ENTB
Yes, it looked good and it closed nicely at 1.81, with nothing to indicate that there's any real trouble on the horizon. I'd like to see it hit 2 for a couple of reasons, not least of which is that capital investment loves a winner, thereby attracting even more capital investment.
2 would certainly be a milestone, no doubt. A hypothetical; what if ENTB can hit that mark? How hard would it be for the stock to improve from there? Personally, I think there's still room for positive improvement as word of its information suites and their capabilities gains wider notice. Maybe I can bribe one of those fellows from "Bulls and Bears" on Fox News Channel to take a look at it?
At any rate, with Borgin on board and heading up its biomed research capability I have a lot of confidence that the quality and success of its clinical trials protocols are going to attract more than enough attention from certain medical research firms. ENTB looks like it's got a strong hand to play these days now that it's got the biomed side of the house in order.
I don't know long it'll take to hit the 52-week high (6.50) again but if it can keep close, at the end of the day, to its daily high (it was 1.82 today, I think), after sell-offs and such, I think investor confidence improves.
Certainly, it's made a few strong moves in the stem cell extraction instrumentation field and I've had a chance to read its recent publication in the Journal of Translational Medicine ("Lasers, stem cells, and COPD"). It's very exciting.
Thanks for the Observation about the ENTB Post
I feel that the biomed and med tech industries are on the cusp of a number of real breakthroughs when it comes to how we look at diseases and then how we treat them. It appears as if ENTB has the correct outlook on just how such medical conditions need to examined, which is what makes the company a real looker at present.
Because there'll be a cash influx from the government into the biomed research field, there'll be an opportunity for companies on the data collection and collation end of things to really make a mark because, once the so-called "grunt work" has been done, downstream costs are lower and companies like ENTB can profit (which still isn't illegal in America, after all on their labors.
At present, ENTB looks to still be bumping up against what many here are saying is its ceiling but the markets today, on the heels of the passage of "ObamaCare" (health care reform) are generally on an upward climb, especially the pharmas and the large health systems. Also, companies like ENTB can expect -- if they have an effective executive suite (and it looks like ENTB does) -- to work closely with government entities like the National Institutes for Health (NIH) and Centers for Disease Control (CDC).
I think that, mainly, this will be because a generic version of a bioinformatics program has many implications for research into communicable diseases such as malaria, tuberculosis and some of the really nasty viral diseases such as Ebola and Marburg virus.
At least, I'm hoping that the case because I've been in some parts of the world where a number of these kinds of diseases are rampant (not Ebola and Marburg, thank goodness) and if we can assemble a database of everything known about such diseases under one system we can better design effective treatments, therapies and even (hopefully) cures.
ENTB looks to be a real player in this end of the medical world, right now, which is why I'm of a positive mind about it.
ENTB and Corporate Social Responsibility
Agree with the socially responsible aspects of what ENTB is doing. It's also a bit of proof that companies can do the right thing, for the right reasons, and be rewarded by stockholders and those looking at investing in a company that has a very solid foundation on which it'll build in the future.
From looking at ENTB's literature and from what I've learned from other sources, it's hard to see a downside in terms of what it's doing as it relates to bioinformatics and the data it'll allow to be gathered and then applied to stem cell therapies and other avenues that may finally find the magic bullet, so to speak.
In fact, it might be in the strongest position to capitalize on its lead in this field, which could strengthen its bottom line, which would then allow it to expand in a thoughtful manner and from a position of strength. This would, of course, allow ENTB to put even more resources into the fight while also strengthening the reward to its investor base.
Looks like there's plenty of upward movement available for ENTB and few risks of a significant downward slide for it in the future, given that the Obama administration and the National Institutes for health are focused on encouraging these types of research and therapy efforts vice just addressing the condition symptomatically. That's very good news.
Now, if only ENTB can do for me what my Ford stock has been doing lately (I traded all my DAL stock for Ford last year, when it was below 2.70 and I’m loving life right now). All would definitely be right with the world then!
COPD Deserves the Attention; Glad ENTB's On It
I'm liking what I'm seeing in regards to the fight that finally seems to be going on in the obstructive pulmonary disease field. I've been a PA and a healthcare administrator (now relaxing by playing with OTCs and the like) and the hospital medical materials department I ran was constantly looking for ways to help the medical research folks get the tools they needed (it was at the Naval Medical Center in Bethesda, MD) so that they could try to "connect the dots" more effectively.
The issue with this field (as it is whenever a huge amount of data is circulating out there, whether it's medical intelligence or military intelligence or the like) is that separating the wheat from the chaff becomes hugely important. One can do it, using more traditional tools, but epidemiological data collection and analysis -- even with the best investigatory tools available -- is extremely difficult. However, an bioinformatics suite can make it easier by a full order of magnitude. That's what's exciting about ENTB's little innovation.
Certainly, I'm hoping it's a big seller on the market, not only because it looks to be highly effective and it'll make for a potential high-selling product, but (more importantly) it may finally have given researchers a way to begin to find that elusive needle in a haystack or even, the single tiny grain of sand in a 200-mile long stretch of beach, that's how it's thought that some of these disease processes work (at the microcellular level).
Given that, I think the company's looking good, and for all the right reasons.